Manhattan Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing pharmaceutical therapies for underserved patient populations. The Company has four product candidates in development: Hedrin, a non-insecticide treatment for pediculosis (head lice); Topical PTH (1-34) for the treatment of psoriasis; Altoderm (topical cromolyn sodium) for the treatment of pruritus associated with dermatologic conditions, including atopic dermatitis, and Altolyn (oral tablet cromolyn sodium) for the treatment of mastocytosis. As of December 31, 2007, Manhattan Pharmaceuticals had not received regulatory approval for, or generated commercial revenues from marketing or selling any drugs.
(Source: 10-K)
